DCB-USA LLC
Wilmington, DE US
DCB-USA LLC Patent applications | ||
Patent application number | Title | Published |
---|---|---|
20160136176 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 05-19-2016 |
20160130336 | ANTI-VEGF ANTIBODIES AND USE THEREOF - An anti-VEGF antibody, or a binding fragment thereof, includes a heavy-chain variable region that comprises: (1) a CDRH1 sequence selected from SEQ ID NO: 17, 20, 23, 26, 29, 32, 35, or 38), (2) a CDRH2 sequence selected from SEQ ID NO:18, 21, 24, 27, 30, 33, 36, or 39, and (3) a CDRH3 sequence selected from SEQ ID NO:19, 22, 25, 28, 31, 34, 37, or 40; and a light-chain variable region that comprises: (1) a CDRL1 sequence selected from SEQ ID NO: 41, 44, 47, 50, 53, 56, 59, or 62, (2) a CDRL2 sequence selected from SEQ ID NO: 42, 45, 48, 51, 54, 57, 60, or 63, and (3) a CDRL3 sequence selected from SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, or 64. A method for treating or preventing a VEGF-related disorder, e.g., diabetic retinopathy, age-related macular degeneration, or cancer, uses the antibodies. | 05-12-2016 |
20150218251 | MODIFIED FIBRONECTIN FRAGMENTS OR VARIANTS AND USES THEREOF - The present invention provides isolated polypeptides comprising a modified fibronectin fragment that comprises FNIII 10 and optionally further comprising FNIII 9. Also provided are pharmaceutical compositions comprising the polypeptides and methods of making and using the polypeptides. | 08-06-2015 |
20140178360 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 06-26-2014 |
20130165629 | BISPECIFIC T-CELL ACTIVATOR ANTIBODY - This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity. | 06-27-2013 |
20120288492 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 11-15-2012 |
20120282260 | ANTI-HERPES SIMPLEX VIRUS ANTIBODIES AND METHODS OF USE THEREOF - The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections. | 11-08-2012 |
20110236424 | TREATING ALLERGY WITH DETOXIFIED E. COLI HEAT-LABILE ENTEROTOXIN - A method for treating allergy with a pharmaceutical composition containing a detoxified | 09-29-2011 |
20110166141 | CATHEPSIN S INHIBITORS - Cathepsin S inhibitors having formula (I), (II), (III) or (IV) as shown in the specification. These inhibitors can be used to treat cancer and autoimmune/inflammatory diseases. | 07-07-2011 |
20110039880 | ARYL SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS - Aryl substituted sulfonamide compounds of formula (I): | 02-17-2011 |
20100190732 | USE OF PTEROSIN COMPOUNDS FOR TREATING DIABETES AND OBESITY - This invention relates to the use of pterosin compounds of formula I for treating diabetes including type I and type II. Also disclosed is the use of the pterosin compounds for treating obesity. | 07-29-2010 |
20100160414 | Treating Picornavirus Infection by Targeting MicroRNA miR-141 - Treatment of picornavirus infection by inhibiting miR-141 activity. Also disclosed herein are a method for identify miR-141 inhibitory compounds and a method for identifying a target viral infection to be treated by anti-miR-141 therapy. | 06-24-2010 |
20090162378 | ANTI-HUMAN CYTOMEGALOVIUS ANTIBODIES - The present invention features a human antibody that specifically binds to human cytomegalovirus (HCMV), its encoding nucleic acid(s), and use of the antibody/nucleic acid(s) in treating HCMV infection. | 06-25-2009 |